Therapeutic brands help lift Aspen Pharmacare's H1 profit

8th March 2018

By: Reuters

  

Font size: - +

South Africa's Aspen Pharmacare said on Thursday first-half earnings rose 26%, buoyed by a strong result from therapeutic focused brands and positive performance of the pharmaceutical business in its home market.

Aspen, which counts developed Europe as its biggest revenue generator, has been transforming itself into a therapeutically focused multinational pharmaceutical group rather than one that just makes tablets.

It has looked to injectibles such as anaesthetics to increase sales, building up its business in the past year with the commercial rights to AstraZeneca drugs and products from GlaxoSmithKline.

Aspen, with presence in 50 countries spanning six continents, said normalised headline earnings per share (HEPS) for the six-months ended December 31, rose to 872 cents from 692 cents.

HEPS is the main profit gauge in South Africa, which strips out certain one-off items.

Group revenue grew 11% to R21.9-billion from R19.8-billion.

"The significant influences on performance were: healthy organic growth driven by continued positive momentum in performance from the South African pharmaceutical business and a strong result from the Thrombosis brands," the firm said in a statement.

Therapeutic focused brands comprising the Anaesthetics, Thrombosis and High Potency and Cytotoxic portfolios, delivered revenue of R9.9-billion, contributing 45% of total group revenue.

Sub-Saharan Africa was the primary growth driver in regional pharmaceutical brands, underpinned by the South African business which raised revenue 21%.

"The sales achieved in the first half of the 2018 financial year are expected to be maintained in the second half in spite of the continued supply constraints which will prevent realisation of full potential," the firm said.

It also said performance in the second half will benefit from the additional rights to the AstraZeneca Anaesthetics, which it acquired in October.

Edited by Reuters

Comments

The content you are trying to access is only available to subscribers.

If you are already a subscriber, you can Login Here.

If you are not a subscriber, you can subscribe now, by selecting one of the below options.

For more information or assistance, please contact us at subscriptions@creamermedia.co.za.

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION